cv eitan.amir 201751175337 - comprehensive …eitan amir page 4 of 27 generated by web cv - 2017 may...

Curriculum Vitae

Eitan Amir MB ChB (Hons), PhD, MRCP (UK)

A. Date Curriculum Vitae is Prepared: 2017 May 11

B. Biographical Information

Primary Office Princess Margaret Cancer Centre 700 University Ave Room 7-721 Toronto, Ontario M5G 1Z5 Telephone 416-946-4501 Ext 5181 Fax 416-946-6546 Email [email protected]

1. EDUCATION

Degrees

2008 Jul - 2012 Jul PhD, Clinical Epidemiology, Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada, Supervisor(s): Dr. Ian Tannock

1998 Sep - 2003 Jul MB ChB (Honours), Dept of Medicine, University of Manchester, Manchester, United Kingdom

Postgraduate, Research and Specialty Training

2008 Jul - 2012 Jan 4 Clinical Fellow, Medical Oncology, Princess Margaret Hospital, Toronto, Ontario

2006 Aug - 2008 Jun Medical Oncology Training Scheme, Christie Hospital and Holt Radium Institute, Manchester, United Kingdom

2004 Aug - 2006 Aug General (Internal) Medicine Training, South of Manchester Medicine Training Scheme, Wythenshawe Hospital, Manchester, United Kingdom

2003 Aug - 2004 Aug Medical and Surgical Internship, General (Internal) Medicine, Trafford General Hospital, Manchester, United Kingdom

2003 Aug - 2004 Aug Medical and Surgical Internship, General Surgery and Urology, Stepping Hill Hospital, Stockport, United Kingdom

Qualifications, Certifications and Licenses

2006 Apr MRCP (UK)

Eitan AMIR

of 27 Generated by Web CV - 2017 May 11

CONFIDENTIAL DOCUMENT

2. EMPLOYMENT

Current Appointments

2013 May - present Associate Professor, Health Policy, Management and Evaluation, Clinical Epidemiology, University of Toronto

2012 Jan 5 - present Active Staff, Oncology, Medicine, Princess Margaret Hospital, Canada

2012 Jan 5 - present Associate Professor, Oncology, Medicine, University of Toronto

2012 Jan 5 - present Associate Staff, Oncology, Medicine, Mount Sinai Hospital, Canada

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

INTERNATIONAL

Received 2016 Aug Outstanding Contribution in Reviewing, Elsevier and the European Organisation for

Research and Treatment of Cancer. (Research Award)

2014 Nov Outstanding Contribution in Reviewing, Elsevier and the European Organisation for Research and Treatment of Cancer. (Research Award)

2011 Jun ASCO Cancer Foundation Merit Award, American Society for Clinical Oncology. (Distinction)

2010 Sep International Bone and Mineral Society Travel Grant, 10th International Meeting on Cancer Induced Bone Disease. (Distinction)

2010 Jun ASCO Cancer Foundation Merit Award, American Society for Clinical Oncology. (Distinction)

2010 Jun Novartis Oncology Young Canadian Investigator Award, American Society for Clinical Oncology. (Distinction)

2009 Dec AACR Translational Research Scholarship, San Antonio Breast Cancer Symposium. (Research Award)

2009 May - 2009 Jun ASCO Cancer Foundation Merit Award, American Society for Clinical Oncology. (Distinction)

LOCAL

Received 2015 Jun Young Investigator Award, University of Toronto. (Research Award)

Nominated 2017 Michael Kamin Hart Award, Princess Margaret Cancer Centre - Adolescent & Young Adult

Program. (Distinction)

2012 Jan - 2012 Dec Clinical and translational paper of the year, Princess Margaret Cancer Centre / Ontario Cancer Institute. (Research Award)

Eitan AMIR



Teaching and Education Awards

LOCAL

Received 2015 Jul - 2016 Jun Outstanding Teaching Award, Faculty of Medicine, University of Toronto Medical Oncology

Training Program

2012 Jul - 2013 Jun Outstanding Teaching Award, Faculty of Medicine, University of Toronto Medical Oncology Training Program

Student/Trainee Awards

LOCAL

Received 2015 Sep - 2016 Mar Fall 2015 School of Graduate Studies Conference Grant, Medical Oncology, Research

Supervisor, Awardee Name: Amirrtha Srikanthan. University of Toronto, Toronto, Ontario, Canada Financial support to eligible students who are actively presenting their research at an academic conference. Total Amount: 550 CAD

2015 Jul - 2016 Jun Ontario Student Opportunity Trust Fund, Medical Oncology, Research Supervisor, Awardee Name: Amirrtha Srikanthan. University of Toronto, Toronto, Ontario, Canada Fellowship Award to facilitate completion of clinical fellowship at Princess Margaret Cancer Centre. Total Amount: 10,000 CAD

2015 Jul - 2016 Jun Ontario Student Opportunity Trust Fund, Medical Oncology, Research Supervisor, Awardee Name: Josee-Lyne Ethier. University of Toronto, Toronto, Ontario, Canada Fellowship Award to facilitate completion of clinical fellowship at Princess Margaret Cancer Centre. Total Amount: 10,000 CAD

2014 Jul - 2015 Jun Ontario Student Opportunity Trust Fund, Medical Oncology, Research Supervisor, Awardee Name: Amirrtha Srikanthan. University of Toronto, Toronto, Ontario, Canada Fellowship Award to facilitate completion of clinical fellowship at Princess Margaret Cancer Centre. Total Amount: 20,000 CAD

2014 Jan - 2014 Jul DMOH Fellows Research Award, Medical Oncology, Research Supervisor, Awardee Name: Francisco Vera-Badillo. Princess Margaret Cancer Centre, Toronto, Ontario, Canada Research Award to facilitate completion of project entitled “Association between Androgen Receptor (AR) Expression, Ki67 and the 21-Gene Recurrence Score in Early Breast Cancer.”. Total Amount: 12,500 CAD

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Administrative Activities

INTERNATIONAL

Cancer and Work Network

2016 Jan - 2016 Dec Medical Advisor, Trainer, Amsterdam, Unknown, Netherlands.

Fondazione Michelangelo

2014 Apr - 2014 Nov Member, Faculty Member, Milan, Milano, Italy.

Eitan AMIR



Food and Drug Administration (US)

2015 Dec 9 - present Member, Bone metastasis trials working group, Silver Spring, Maryland, United States.

Institut National du Cancer (French National Cancer Institute)

2013 Jan Member, External Reviewer, Boulogne-Billancourt, Paris, France.

National Cancer Institute (US)

2012 Mar 19 - 2014 Mar 31 Member, Breast Cancer Steering Committee, Bethesda, Maryland, United States.

NATIONAL

Bone and the Oncologist (BONUS)

2009 Jan - 2016 Jun Member, Conference Organizing Committee, Ottawa, Ontario, Canada.

LOCAL

Cancer Care Ontario

2012 Jul - present Lead, Regional Systemic Therapy, Regional Cancer Program, Ontario, Canada.

Princess Margaret Cancer Centre

2016 Oct - present Vice Chair, Research Ethics Board, Cancer

2008 Sep - 2016 Sep Member, Research Ethics Board, Cancer

Princess Margaret Hospital

2012 Jul 16 Lead, Regional Systemic Treatment Quality Lead for Toronto Central South

University of Toronto

2016 Jun - present Member, Division of Medical Oncology Executive, Toronto, Ontario, Canada.

Peer Review Activities

EDITORIAL BOARDS

Reviewer

2016 Apr - present Molecular Diagnosis and Therapy

2014 Jan 1 - 2019 Dec Journal of Clinical Oncology

GRANT REVIEWS

External Grant Reviewer

2016 Dec - 2017 Feb Medical Research Council, Number of Reviews: 1

2015 Sep Canadian Cancer Society, Number of Reviews: 67

2014 Faculty of Medicine, Imperial College London, Number of Reviews: 1

2014 KWF Kankerbestrijding (Dutch Cancer Society), Number of Reviews: 1

2013 - 2014 French National Cancer Institute (INCa), Number of Reviews: 4

2012 Canadian Breast Cancer Foundation, Number of Reviews: 1

Eitan AMIR



2012 Cancer Research UK, Number of Reviews: 1

2012 Israel Science Fund, Number of Reviews: 1

2011 - 2014 Quebec Breast Cancer Foundation, Number of Reviews: 2

MANUSCRIPT REVIEWS

Reviewer

2011 - present European Journal of Cancer, Number of Reviews: 15

2010 - present Journal of Clinical Oncology, Number of Reviews: 39

2010 - present Journal of the National Cancer Institute, Number of Reviews: 10

2016 BMJ - British Medical Journal, Number of Reviews: 1

2016 British Journal of Cancer, Number of Reviews: 1

2016 JAMA Oncol, Number of Reviews: 3

2016 Molecular Diagnosis & Therapy, Number of Reviews: 2

2016 The Breast, Number of Reviews: 1

2015 Breast Cancer Research, Number of Reviews: 1

2015 Breast Cancer Research and Treatment, Number of Reviews: 1

2015 Expert Opinion On Pharmacotherapy, Number of Reviews: 2

2015 Oncotarget, Number of Reviews: 1

2014 Cancer Causes and Control, Number of Reviews: 1

2013 Annals of Oncology, Number of Reviews: 1

2013 Cancer Treatment Reviews, Number of Reviews: 2

2013 Drugs, Number of Reviews: 1

2012 CA: A Cancer Journal for Clinicians, Number of Reviews: 1

2011 - 2017 Lancet Oncology, Number of Reviews: 3

2011 - 2016 JAMA, Number of Reviews: 3

2011 - 2013 Annals of Surgical Oncology, Number of Reviews: 3

2011 Cancer Epidemiology, Biomarkers & Prevention, Number of Reviews: 1

2011 Clinical Epidemiology, Number of Reviews: 1

2011 Nature Review Clinical Oncology, Number of Reviews: 1

2010 British Journal of Cancer, Number of Reviews: 1

2010 Current Oncology, Number of Reviews: 3

2010 Expert Opinion On Pharmacotherapy, Number of Reviews: 1

2009 - 2014 Supportive Care in Cancer, Number of Reviews: 5

2009 - 2014 The Oncologist, Number of Reviews: 1

2009 Cancer, Number of Reviews: 2

2009 Future Oncology, Number of Reviews: 1

2009 PLoS One, Number of Reviews: 1

LAY REVIEW OF RESEARCH DEVELOPMENTS

Reviewer

2015 Canadian Cancer Society

PROFESSIONAL CONSULTATION

Reviewer

Eitan AMIR



2013 Feb - 2015 Apr Cancer Care Ontario, Program in Evidence-based Care, Number of Reviews: 4

C. Academic Profile

1. RESEARCH STATEMENTS

2012 Jan - present Research Overview. I completed a PhD in Clinical Epidemiology in 2012 and subsequently received my Faculty appointment at The University of Toronto. Since my appointment, I have based my research and scholarly work on my PhD training with an emphasis on three broad themes: knowledge synthesis in cancer medicine (with a focus on statistical modeling, systematic review and meta-analysis), research methodology as well as large database research. I co-founded and co-lead an international collaborative of investigators aimed at conducting high quality knowledge synthesis-based research in oncology (Co-lead: Alberto Ocana, Albacete, Spain). This collaborative which comprises investigators in four countries has been a source of a high level of research productivity and has also provided research opportunities for medical oncology residents and clinical fellows.

Professional Interests. I intend to pursue a career in Academic Medical Oncology. Clinical interests include breast cancer and cancer prevention. Academic interests include meta-analysis, risk assessment and clinical epidemiology.

2. TEACHING PHILOSOPHY

My philosophy for clinical teaching is to allow trainees the freedom to gather their own information independently and then formulate a management plan for patients. I also view clinical encounters with patients as an opportunity for collaborative patient management. I use individual patient cases to highlight key evidence-based teaching points and ask questions that stimulate further independent thinking. My approach to research supervision is similar. It is important for trainees to develop their own ideas and I actively encourage this. I also expect research trainees to take appropriate responsibility for research, while providing support and guidance. Many of the clinical fellows who come to our department for further training have limited prior experience with research and are especially limited in their writing skills. I learned from my own fellowship supervisor, Dr. Ian Tannock how to continually encourage development of writing skills. As such, I perform extensive edits to trainees work allowing them to improve their skills by learning from my reviews. As a didactic teacher, I think it is crucial to show enthusiasm roe the material being taught. I also try to involve the audience in lectures whenever possible and also use real world examples of both good and bad examples of clinical and research endeavours.

Eitan AMIR



D. Research Funding

1. GRANTS, CONTRACTS AND CLINICAL TRIALS

PEER-REVIEWED GRANTS

FUNDED

2017 Jul - 2020 Jun Co-Investigator. Novel cell-free DNA assays to predict relapse and guide systemic therapy in early breast cancer. Canadian Cancer Society Breast Cancer Research Grants. PI: David Cescon. Collaborator(s): Eitan, Amir, Philippe Bedard, Scott Bratman, Martin Chang, Stephen Chia, Susan Done, David McCready, Hal Berman, Pamela Goodwin, Zachary Veitch. 450,000 CAD. [Grants]

2017 Apr - 2019 Mar Co-Principal Investigator. Randomized double controlled trial of Statins for the Primary pREvention of Heart Failure in patients with cancer receiving anthracycline based chemotherapy (The SPARE HR Pilot study). AHSC AFP Innovation Fund. PI: Thavendiranathan P, Amir E. Collaborator(s): Wintersperger, Bernd ; Maze, Dawn ; Farkouh, Michael ; Billia, Phyllis ; Prica, Anca. 184,000 CAD. [Grants]

2017 Feb - 2019 Jan Co-Investigator. Adaptation, feasibility and acceptability study of the advanced symptom monitoring and management system (ASyMS) mobile health intervention to reduce chemotherapy toxicities in Canadian cancer patients. Canadian Cancer Society Research Institute. PI: Doris Howell and Monika Krzyzanowska. Collaborator(s): Roma Maguire, Vishal Kukreti, Geoffrey Liu, Joe A. Cafazzo, Plinio Morita, Saeed Moradian, Jackie Bender, Lisa W. Le, Amna Husain, Maria M. Puts, Eitan Amir. 200,000 CAD. [Grants]

2016 Apr - 2018 Mar Co-Investigator. The impact and management of cardiovascular disease in Ontario women diagnosed with early stage breast cancer. Heart and Stroke Foundation. PI: Geoffrey Anderson. Collaborator(s): Abdel-Qadir, Husam; Amir, Eitan; Austin, Peter; Lee, Douglas; Thavendiranathan, Paaladinesh; Tu, Jack. 70,810 CAD. [Grants]

2015 Jul - 2018 Jul Co-Investigator. Evaluation of myocardial changes during breast adenocarcinoma therapy to detect cardiotoxicity earlier with MRI - The EMBRACE MRI Study. Canadian Institutes of Health Research (CIHR). PI: Thavendiranathan, P and Wintersperger, B. Collaborator(s): Ahmed, S; Amir, E; Bedard, P; Brezden-Masley, C; Liu, G; Udell, J; Verma, S; Yan, A. 641,000 CAD. [Grants]

2015 Jul - 2017 Jan Principal Investigator. Association between peripheral blood neutrophil-to-lymphocyte ratio, tumor-infiltrating lymphocytes and the 21-gene recurrence score in women with lymph-node negative, estrogen receptor-positive and HER2/neu-negative breast cancer. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. 24,000 CAD. [Grants] Analysis of the association between peripheral blood neutrophil-to-lymphocyte ratio (NLR), tumor-infiltrating lymphocytes and the 21-gene recurrence score in women with lymph-node negative, estrogen receptor-positive and HER2/neu-negative breast cancer. The study involved use of archival tissue from breast cancer patients and its assessment for tumor-infiltrating lymphocytes . The primary aim was to quantify the association between tumor-infiltrating lymphocytes and both the 21-gene recurrence score and peripheral blood NLR.

2014 Sep - 2015 Aug Principal Investigator. Trade-off decisions for fertility preservation in young women with breast cancer needing chemotherapy. Ontario Student Opportunity Trust Fund. Collaborator(s): Srikanthan A, Kennedy E, McLeod R. 20,000 CAD. [Grants] Provide partial salary support to employ a clinical fellow to complete a cohort study

Eitan AMIR



assessingtrade-offs between effective anti-breast cancer therapy and risk of infertility.

2014 Sep - 2015 Aug Co-Principal Investigator. Influence of the pan-Canadian Oncology Drug Review (pCODR) on approval and time to funding of anti-cancer drugs. Ontario Drug Policy Research Network. Collaborator(s): Srikanthan A, Laupacis A, Chan K. 17,500 CAD. [Grants] Provide partial salary support for clinical fellow to complete study of the influence of the pan-Candian Oncology Drug Review program on the consistence and timing of approval of anti-cancer drugs.

2014 Jul - 2015 Jun Co-Investigator. Evaluation of myocardial changes during breast adenocarcinoma therapy to detect cardiotoxicity earlier with MRI - The EMBRACE MRI Study. Canadian Institutes of Health Research (CIHR). PI: Thavendiranathan, P and Wintersperger, B. Collaborator(s): Ahmed, S; Amir, E; Bedard, P; Brezden-Masley, C; Udell, J; Verma, S; Yan, A. 100,000 CAD. [Grants]

2013 Oct - 2015 Oct Co-Investigator. What is the role of comorbidity, frailty and functional status in the decision-making process for older adults with cancer and their family members, cancer specialist, and family physician? Canadian Cancer Society Innovation Grants. PI: Puts, Maria. Collaborator(s): Alibhai S., Amir E., Fitch M., Joshua A., Kryzanowska M, Leighl N., Tourangeau A., Warde P. 74,722 CAD. [Grants]

2013 Jul - 2015 Jun Principal Investigator. Association between Androgen Receptor (AR) Expression, Ki67 and the 21-Gene Recurrence Score in Early Breast Cancer. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. 12,500 CAD. [Grants] Analysis of the association of the Androgen Receptor with a genomic risk score frequently used in breast cancer. The study involved use of archival tissue from breast cancer patients and its assessment for Androgen Receptor expression. The primary aim was to quantify the association between the degree of Androgen Receptor expression and the 21-gene recurrence score.

2012 Oct - 2013 Sep Co-Investigator. Prospective Identification of Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases. PROVIST 2. (PROVIST 2 biomarker project). Ontario Institute for Cancer Research. PI: Clemons, M. Collaborator(s): Cheung, Angela (Co-I); Addison, Christina (Co-I); Hutton, Brian (Co-I). 59,074 CAD. [Grants]

2012 Jul - 2013 Jun Co-Investigator. Development of a questionnaire to measure Fatigue related late effects for breast cancer patients and its impact on productivity and quality of life. Canadian Centre for Applied Research in Cancer Control. PI: Jones, JM. Collaborator(s): Bedard, P (Co-I); Longo, C (Co-I); Howell D (Co-I); Olser, K (Co-I). 26,000 CAD. [Grants]

2011 Jun - 2013 Jun Co-Investigator. Pilot study of a brief telephone-based intervention (adhERe) to improve adherence to adjuvant hormone therapy in women with early stage breast cancer. Canadian Breast Cancer Foundation (CBCF). PI: Jones, JM. Collaborator(s): Bedard, Philippe (Co-I); Catton, Pamela (Co-I); Blackburn, David (Co-I); Grunfeld Eva (Co-I); Guimond, Tim (Co-I); Sisler, Jeff (Co-I); Steven, Joanne (Co-I); Stricker, Carrie (Co-I); Secord, S (Collaborator); Carlsson, L (Collaborator); Le L (Collaborator). 144,764 CAD. [Grants]

2010 Jul - 2013 Jun Co-Investigator. A Multicentre Phase II Study Assessing 12-weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases From Breast Cancer Using Bone Resorption Markers. Canadian Breast Cancer Foundation (CBCF). PI: Clemons, M. Collaborator(s): Hilton, J (Co-I); Dent, R (Co-I); Dent S (Co-I); Freedman, O (Co-I); Dranitsaris, G (Co-I); Ooi, D (Co-I); Kanji, F (Co-I). 288,500 CAD. [Grants]

Eitan AMIR



NON-PEER-REVIEWED GRANTS

FUNDED

2014 Feb Principal Site Investigator. Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index (COMETI P2). Janssen Diagnostics, LLC. [Clinical Trials]

2013 Jan Principal Site Investigator. Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. NCIC CTG. [Clinical Trials]

E. Publications

1. PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Natori A, Ethier JL, Amir E, Cescon DW. Capecitabine in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Eur J Cancer. 2017 May;77:40-47. Impact Factor 6.163. Coauthor or Collaborator.

2. Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano L, Galán E, Amir E, Pandiella A, Győrffy B, Ocaña A. Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. PLoS One. 2017 May;12(5):e0175128. Impact Factor 3.057. Coauthor or Collaborator.

3. Ribnikar D, Ratoša I, Perhavec A, Amir, E. The treatment of young women with breast cancer. Rev Invest Clin. 2017 Apr;69(2):77-93. Impact Factor 0.477. Senior Responsible Author.

4. Barnes TA, Amir E, Templeton AJ, Gomez Garcia S, Navarro B, Seruga B, Ocana A. Efficacy, Safety, Tolerability and Price of Newly Approved Drugs in Solid Tumors. Cancer Treat Rev. 2017 Apr;56:1-7. Impact Factor 7.983. Co-Principal Author.

5. Chiramel J, Backen A, Pihlak R, Lamarca A, Frizziero M, Tariq N, Hubner R, Valle JW, Amir E, McNamara MG. Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review. Int J Mol Sci. 2017 Apr;18(5):909. Impact Factor 3.257. Coauthor or Collaborator.

6. Hansen AR, Cook N, Amir E, Siu LL, Abdul Razak AR. Determinants of the Recommended Phase II Dose of Molecular Targeted Agents. Cancer. 2017 Apr;123(8):1409-1415. Impact Factor 5.649. Coauthor or Collaborator.

7. Ethier JL, Prince RM, Amir E. Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer. Curr Oncol Rep. 2017 Mar;19(3):15. Impact Factor 2.653. Senior Responsible Author.

8. Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A. Mitotic read-out genes for poor outcome in luminal A breast cancer tumors. Oncotarget. 2017 Mar;8(13):21733-21740. Impact Factor 6.36. Coauthor or Collaborator.

9. Abdel-Qadir H, Ong G, Fazelzad R, Amir E, Lee DS, Thavendiranathan P, Tomlinson G. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol. 2017 Mar;28(3):628-633. Impact Factor 9.269. Coauthor or Collaborator.

10. Puts M, Sattar S, McWatters K, Lee K, Kulik M, Macdonald ME, Jang R, Amir E, Krzyzanowska M, Leighl N, Fitch M, Joshua A, Warde P, Tourangeau A, Alibhai S. Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. Support Care Cancer. 2017 Mar;25(3):879-886. Impact Factor 2.535. Coauthor or Collaborator.

Eitan AMIR



11. Abdel-Qadir HM, Ethier JL, Thavendiranathan P, Lee DS, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017 Feb;53:120-127. Impact Factor 7.983. Senior Responsible Author.

12. Ethier JL, Desautels D, Templeton A, Shah P, Amir E. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res. 2017 Jan;19(1):2. Impact Factor 5.211. Senior Responsible Author.

13. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, Fung K, Anderson GM. A Population-Based Study of Cardiovascular Mortality following Early-Stage Breast Cancer: The Clinical Importance of Competing Risks. JAMA Cardiol. 2017 Jan;2(1):88-93. Coauthor or Collaborator.

14. Iqbal J, Amir E, Rochon PA, Giannakeas V, Sun P, Narod SA. Impact of the Timing of Pregnancy on Survival in Women with Breast Cancer. JAMA Oncol. 2017. In Press. Coauthor or Collaborator.

15. Tibau A, Díez-González L, Navarro B, Templeton AJ, Seruga B, Pandiella A, Amir E. Ocana A. Impact of availability of companion diagnostics on clinical development of anti-cancer drugs. Mol Diagn Ther. 2017. In Press. Impact Factor 2.563. Coauthor or Collaborator.

16. Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the Neutrophil-to-Lymphocyte Ratio Prognostic of Survival Outcomes in Gynecologic Cancers? A Systematic Review and Meta-Analysis. Gyne Oncol. 2017. In Press. Impact Factor 4.198. Coauthor or Collaborator.

17. Srikanthan A, Mai H, Penner N, Amir E, Laupacis A, Sabharwal M, Chan KKW. The impact of pCODR on provincial concordance of cancer drug funding decisions and time to funding. Curr Oncol. 2017. In Press. Impact Factor 1.829. Coauthor or Collaborator.

18. Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. The relevance of randomized controlled trials to clinical practice. Lancet Oncol. 2016 Dec;17(12):e560-e567. Impact Factor 26.509. Coauthor or Collaborator.

19. Thomas GR, McDonald MA, Ross HJ, Delgado DH, Billia F, Butany JW, Rao V, Amir E, Bedard P, Thavendiranathan P. A Matched Cohort Study of Patients with End-stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support. Am J Cardiol. 2016 Nov;118(10):1539-1544. Impact Factor 3.154. Coauthor or Collaborator.

20. Vera-Badillo FE, Napoleone M, Krzyzanowska M, Alibhai S, Chan AW, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF. Honorary and Ghost-Authorship in Reports of Randomized Clinical Trials in Oncology. Eur J Cancer. 2016 Oct;66:1-8. Impact Factor 6.163. Coauthor or Collaborator.

21. Ethier JL, Amir E. The role of the 21-gene recurrence score in breast cancer treatment. Mol Diagn Ther. 2016 Aug;20(4):307-313. Impact Factor 2.891. Senior Responsible Author.

22. Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ, Rochon PA, Lee DS, Anderson GM. The Risk of Myocardial Infarction Associated with Aromatase Inhibitors or Tamoxifen in the Treatment of Early Stage Breast Cancer. Eur J Cancer. 2016 Aug;68:11-21. Impact Factor 6.163. Coauthor or Collaborator.

23. Templeton AJ , Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, Heng DYC. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol. 2016 Aug;70(2):358-64. Impact Factor 13.938. Coauthor or Collaborator.

24. Ocaña A, Díez-González L, Esparís-Ogando A, Montero JC, Amir E, Pandiella A. Neuregulin expression in solid tumors: prognostic value and predictive role for anti-HER3 therapies. Oncotarget. 2016 Jul;7(29):45042-45051. Impact Factor 6.36. Coauthor or Collaborator.

25. Nathan PC, Amir E, Abdel-Qadir H. Cardiac outcomes in survivors of pediatric and adult cancers. Can J Cardiol. 2016 Jul;32(7):871-80. Impact Factor 3.711. Coauthor or Collaborator.

Eitan AMIR



26. Abdel-Qadir H, Amir E, Thavendiranathan P. Prevention, Detection and, Management of Chemotherapy Related Cardiac Dysfunction. Can J Cardiol. 2016 Jul;32(7):891-9. Impact Factor 3.711. Coauthor or Collaborator.

27. Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, Lee DS. Breast Cancer Therapy-Related Cardiac Dysfunction In Adult Women Treated in Routine Clinical Practice – A Population Based Cohort Study. J Clin Oncol. 2016 Jul;34(19):2239-2246. Impact Factor 20.982. Coauthor or Collaborator.

28. Srikanthan A, Amir E, Warner E. Association between a dedicated program for young breast cancer patients and discussion about fertility preservation. Breast. 2016 Jun;27:22-26. Impact Factor 2.381. Coauthor or Collaborator.

29. Fernandes R, Siegel P, Komarova S, Hilton J, Addison C, Ibrahim MFK, Werier J, Dennis K, Singh G, Amir E, Jarvis V, Emmenegger U, Mazzarello S, Clemons M. Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). J Bone Oncol. 2016 Jun;5:57–62. Coauthor or Collaborator.

30. Tibau A, Ocana A, Anguera G, Seruga B, Templeton AJ, Barnadas A, Amir E. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the U.S. Food and Drug Administration. JAMA Oncol. 2016 Jun;2(6):744-750. Senior Responsible Author.

31. AlHashem HY, Al-Mubarak M, Vera-Badillo FE, Templeton AJ, Ocana A, Seruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol). 2016 May;28(5):283-91. Impact Factor 3.398. Senior Responsible Author.

32. Templeton AJ, Diez Gonzalez L, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A. Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: A systematic review and meta-regression. PLoS One. 2016 May;11(5):e0154789. Impact Factor 3.534. Coauthor or Collaborator.

33. Prince RM, Amir E. Update in treatment of early breast cancer in post-menopausal women. Expert Rev Endocrinol Metab. 2016 May;11(3):243-252. Senior Responsible Author.

34. Vera-Badillo FE, Napoleone M, Krzyzanowska M, Alibhai S, Chan A, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF. Bias in Reporting of Randomized Clinical Trials in Oncology. Eur J Cancer. 2016 May;61:29-35. Impact Factor 5.417. Coauthor or Collaborator.

35. Seruga B, Templeton AJ, Vera Badillo FE, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. Lancet Oncol. 2016 May;17(5):e209–e219. Impact Factor 24.69. Coauthor or Collaborator.

36. Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Corrales-Sánchez V, Nieto-Jiménez C, Templeton AJ, Seruga B, Pandiella A, Amir E. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget. 2016 Apr;7(16):22865-72. Impact Factor 6.36. Senior Responsible Author.

37. Zer A, Prince RM, Amir E, Razak ARA. Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: endpoint selection, surrogacy and quality of reporting. J Clin Oncol. 2016 Apr;34(13):1469-1475. Impact Factor 17.96. Coauthor or Collaborator.

38. Graham J, Pitz M, Gordon V, Grenier D, Amir E, Niraula S. Clinical Predictors of Benefit From Fulvestrant in Advanced Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Cancer Treat Rev. 2016 Feb;45:1-6. Impact Factor 7.588. Coauthor or Collaborator.

39. Srikanthan A, Vera-Badillo F, Ethier JL, Goldstein R, Templeton A, Ocana A, Seruga B, Amir E. Evolution in the Eligibility Criteria of Randomized Controlled Trials for Systemic Cancer Therapies. Cancer Treat Rev. 2016 Feb;43:67-73. Impact Factor 7.588. Senior Responsible Author.

40. Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A. Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. Breast Cancer Res Treat. 2016 Feb;156(1):1-8. Impact Factor 3.94. Coauthor or Collaborator.

Eitan AMIR



41. Zist A, Amir E, Ocana A, Seruga B. Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. Radiol Oncol. 2015 Dec;49(4):402-408. [in press]. Impact Factor 1.912. Coauthor or Collaborator.

42. Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 2015 Nov;6(37):39538-49. Impact Factor 6.36. Senior Responsible Author.

43. Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer. 2015 Nov;23(11):3269-75. Impact Factor 2.495. Coauthor or Collaborator.

44. Seruga B, Ocana A, Amir E, Tannock IF. Failures in Phase III: Causes and Consequences. Clin Cancer Res. 2015 Oct;21(20):4552-60. Impact Factor 8.193. Coauthor or Collaborator.

45. Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM. PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metab. 2015 Oct;22(4):577-89. Impact Factor 17.565. Coauthor or Collaborator.

46. Ocana A, Díez-González L, García- Olmo MD, Templeton AJ, Vera-Badillo F, Escribano MJ, Serrano-Heras G, Sánchez-Corrales V, Seruga B, Andrés-Pretel F, Pandiella A, Amir E. Circulating DNA and outcomes in cancer. Cancer Epidemiol Biomarkers Prev. 2015 Oct;25(2):399-406. Impact Factor 4.125. Senior Responsible Author.

47. Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between Androgen Receptor Expression, Ki-67 and the 21-Gene Recurrence Score in Non-metastatic, Lymph node-negative, Estrogen Receptor-positive and HER2-negative Breast Cancer. J Clin Pathol. 2015 Sep;68:839–843. Impact Factor 2.551. Senior Responsible Author.

48. Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH. Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. J immunother. 2015 Aug;38(7):259-66. Impact Factor 3.354. Coauthor or Collaborator.

49. McNamara M, Walter T, Horgan AM, Amir E, McKeever L, Min T, Wallace E, Hedley D, Krzyzanowska M, Moore M, Cleary S, Gallinger S, Greig P, Serra S, Dawson LA, Knox JJ. Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol. 2015 Aug;38(4):382-7. Impact Factor 2.611. Coauthor or Collaborator.

50. Abdel-Qadir H, Amir E, Thavendiranathan P. The use of myocardial strain and newer echocardiography imaging techniques in cancer patients. Future Oncol. 2015 Jul;11(14):2035-41. Impact Factor 2.611. Coauthor or Collaborator.

51. Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E. Outcomes of estrogen receptor negative and progesterone receptor positive breast cancer. PLoS One. 2015 Jul;10(7):e0132449. Impact Factor 3.534. Senior Responsible Author.

52. Blanchette PS, Lo A, Ng P, Razak A, Amir E, Hogg D, Blackstein ME, Gupta AA. Irinotecan and temozolomide in adults with recurrent sarcoma. J Solid Tumors. 2015 Jul;5(2):105-111. Coauthor or Collaborator.

53. Jacobs C, Zhu X, Amir E, Paterson A, Clemons M. Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the 2014 Annual Bone and the Oncologist New Update meeting. J Bone Oncol. 2015 Jun;4(2):54-58. Impact Factor 1.205. Coauthor or Collaborator.

54. Djalalov S, Beca J, Amir E, Krahn M, Trudeau ME, Hoch JS. Economic Evaluation of Upfront and Sequential Hormone Therapies for Post-Menopausal Women with Hormone Receptor-Positive Early Breast Cancer in Canada. Curr Oncol. 2015 Apr;22(2):84-96. Impact Factor 1.643. Coauthor or Collaborator.

Eitan AMIR



55. van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015 Apr;26(4):743-9. Impact Factor 6.578. Coauthor or Collaborator.

56. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic Therapy for Non-Clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-Analysis. Eur Urol. 2015 Apr;67:740-749. Impact Factor 12.48. Senior Responsible Author.

57. Behan LA, Amir E, Casper RF. Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review. Menopause. 2015 Mar(22):342-50. Impact Factor 2.807. Coauthor or Collaborator.

58. Srikanthan A, Ethier JL, Ocana A, Seruga B, Krzyzanowska MK, Amir E. Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A population-based observational study. PLoS One. 2015 Mar;10(3):e0122735. Impact Factor 3.534. Senior Responsible Author.

59. Srikanthan A, Tran B, Beausoleil M, Jewett MAS, Hamilton RJ, Sturgeon JFG, O’Malley M, Anson-Cartwright L, Chung PWM, Warde PR, Winquist E, Moore MJ, Amir E, Bedard PL. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol. 2015 Feb(33):582-587. Impact Factor 17.96. Coauthor or Collaborator.

60. Tibau A, Bedard PL, Srikanthan A, Ethier J, Vera Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. Author Financial Conflicts of Interest, Industry Funding and Clinical Practice Guidelines for Anti-Cancer Drugs. J Clin Oncol. 2015 Jan 1. 33: 100-6. Impact Factor 17.96. Senior Responsible Author.

61. Calleja A, Poulin F, Khorolsky K, Bedard PL, Amir E, Rakowski H, McDonald M, Delgado D, Thavendiranathan P. Right Ventricular Dysfunction in Patients with Breast Cancer Experiencing Cardiotoxicity During Trastuzumab Therapy. J Oncol. 2015:609194. Coauthor or Collaborator.

62. Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer. 2015;51:721-724. Impact Factor 4.819. Coauthor or Collaborator.

63. Niraula S, Amir E, Vera-Badillo FE, Seruga B, Ocana A, Tannock IF. Risk Of Incremental Toxicities And Associated Costs of New Anticancer Drugs: A Meta-analysis. J Clin Oncol. 2014 Nov. 32: 3634-3642. Impact Factor 17.96. Coauthor or Collaborator.

64. Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil to lymphocyte ratio. Cancer. 2014 Nov. 120: 3346-52. Impact Factor 4.901. Senior Responsible Author.

65. Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus. 2014 Oct. 3: 577. Coauthor or Collaborator.

66. Habbous S, Pang V, Xu W, b, Liu G. Human papillomavirus and host genetic polymorphisms in carcinogenesis: a systematic review and meta-analysis. J Clin Virol. 2014 Oct. 61: 220-9. Impact Factor 3.466. Coauthor or Collaborator.

67. Templeton AJ, Diez Gonzalez L, Ace O, Vera-Badillo F,Šeruga B, Jordán J, Amir E, Pandiella A, Ocaña A. Prognostic Relevance of Receptor Tyrosine Kinase Expression in Breast Cancer: A meta-analysis. Cancer Treat Rev. 2014 Aug. 40: 1048-1055. Impact Factor 6.466. Coauthor or Collaborator.

68. Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Seruga B, Al-Mubarak M, AlHashem H, Tannock IF, Amir E. Effect of Multifocality and Multicentricity on Outcome in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res Treat. 2014 Jul. 2014; 146: 235-244. Impact Factor 4.198. Senior Responsible Author.

Eitan AMIR



69. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Šeruga B, Ocaña A, Tannock IF, Amir E. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2014 Jul. 2014; 23: 1204–12. Impact Factor 4.324. Senior Responsible Author.

70. Erman A, Nugent A, Amir E, Coyte PC. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2014 Jun. 2014; 145: 267-79. Impact Factor 4.198. Coauthor or Collaborator.

71. McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever E, Min T, Amir E, Knox JJ. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014 Jun. 2014; 50: 1581-9. Impact Factor 4.819. Coauthor or Collaborator.

72. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic Role of Neutrophil to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 May. 2014; 106(6): dju124. Impact Factor 15.161. Senior Responsible Author.

73. Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. A Phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. Breast Cancer Res Treat. 2014 Apr. 2014; 144: 615-24. Impact Factor 4.198. Coauthor or Collaborator.

74. Šeruga B, Zadnik V, Grašič Kuhar C, Marinko T, Čufer T, Zakotnik B, Zorman D, Ocana A, Amir E. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer Invest. 2014 Apr. 32: 99-104. Impact Factor 2.06. Senior Responsible Author.

75. Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014 Apr. 2014; 9: e95219. Impact Factor 3.534. Senior Responsible Author.

76. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, Eisenberger MA, Tannock IF. Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer in the TAX 327 trial. J Geriatr Oncol. 2014 Apr. 2014; 5: 119-26. Impact Factor 1.146. Coauthor or Collaborator.

77. Zhu, X., Amir, E., Singh, G., Clemons, M., Addison, C. Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting. J Bone Oncol. 2014 Mar. 2014; 3: 1-4. Impact Factor 1.205. Coauthor or Collaborator.

78. Ocaña A, Freedman O, Amir E, Seruga B, Pandiella A. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer Metastasis Rev. 2014 Mar. 33: 295-307. Impact Factor 6.449. Coauthor or Collaborator.

79. Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E. Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-analysis. PLoS One. 2014 Feb 20. 2014; 9: e88238. Impact Factor 3.534. Senior Responsible Author.

80. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 Jan 1. 106: djt319. Impact Factor 15.161. Senior Responsible Author.

81. Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox J, Moore M, Sridhar S, Joshua A, Pond G, Amir E, Tannock IF. Translating Clinical Trials to Clinical Practice: Outcomes of Men with Metastatic Castration Resistant Prostate Cancer Treated with Docetaxel and Prednisone in and out of Clinical Trials. Ann Oncol. 2013 Dec 1. 2013; 24: 2972-7. Impact Factor 6.578. Coauthor or Collaborator.

82. Al-Mubarak M, Sacher AG, Ocana A, Vera-Badillo F, Seruga B, Amir E. Fulvestrant for Advanced Breast Cancer: A Meta-analysis. Cancer Treat Rev. 2013; 39: 753-758. Impact Factor 6.466. Senior Responsible Author.

Eitan AMIR



83. Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, Garcia-Donas J. Mismatch Repair Status and Clinical Outcome in Endometrial Cancer: A Systematic Review and Meta-Analysis. Crit Rev Oncol Hematol. 2013; 88: 154-67. Impact Factor 4.046. Coauthor or Collaborator.

84. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Randomized Feasibility Study of De-escalated (every 12 weeks) versus Standard (every 3-4-weeks) Intravenous Pamidronate in Women with Low-Risk Bone Metastases from Breast Cancer. Am J Clin Oncol. 2013; 36: 436-442. Impact Factor 2.611. Principal Author.

85. Ocana A, Amir E, Vera-Badillo F, Seruga B, Tannock I. Phase III Trials of Targeted Anti-cancer Therapies: redesigning the concept. Clin Cancer Res. 2013 Sep. 2013; 19: 4931-40. Impact Factor 8.193. Coauthor or Collaborator.

86. Bouganim N, Tsvetkova E, Clemons M, Amir E. Evolution of sites of recurrence after early breast cancer over the last 20 years: Implications for patient care and future research. Breast Cancer Res Treat. 2013; 139: 603-606. Impact Factor 4.198. Senior Responsible Author.

87. Vera-Badillo F, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in Reporting of Endpoints of Efficacy and Toxicity in Randomized Clinical Trials for Women with Breast Cancer. Ann Oncol. 2013; 24: 1238-44. Impact Factor 6.578. Coauthor or Collaborator.

88. Dranitsaris G, Dorward K, Hatzimichael E, Amir E. Clinical Trial Design in Biosimilar Drug Development. Invest New Drugs. 2013; 31: 479-87. Impact Factor 2.927. Senior Responsible Author.

89. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 over-expression and survival in solid tumors: A Meta-analysis. J Natl Cancer Inst. 2013; 105: 266-73. Impact Factor 15.161. Senior Responsible Author.

90. Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, Clemons M. Does Estrogen Play a Role in Response to Adjuvant Bone-Targeted Therapies? J Bone Oncol. 2013. 2013; 2: 167-173. Impact Factor 1.205. Coauthor or Collaborator.

91. Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak ARA. Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort use in Single Agent Phase I Cancer Trials. J Clin Oncol. 2013. 2013; 31: 4260-7. Impact Factor 17.96. Coauthor or Collaborator.

92. Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Amir E. Benefit and Harms of New Anti-Cancer Drugs. Curr Oncol Rep. 2013; 15: 270-5. Impact Factor 2.868. Senior Responsible Author.

93. Kuchuk I, Beaumont JL, Clemons M, Amir E, Addison CL, Cella D. Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. J Bone Oncol. 2013. 2013; 2: 154-157. Impact Factor 1.205. Coauthor or Collaborator.

94. Ocana A, Amir E, Seruga B, Martin M, Pandiella A. The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treat Rev. 2013; 39: 68-76. Impact Factor 6.466. Coauthor or Collaborator.

95. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu F, Mackay HJ, Amir E, Liu G. p53 Arg72Pro Polymorphism, HPV status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-analysis. Clin Cancer Res. 2012; 18: 6407–15. Impact Factor 8.193. Coauthor or Collaborator.

96. Mourskaia AA, Amir E, Dong Z, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Siegel PM. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res. 2012; 14: R149. Impact Factor 5.881. Coauthor or Collaborator.

97. Templeton A, Ocaña A, Šeruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012; 136: 289-93. Impact Factor 4.198. Senior Responsible Author.

98. Seruga B, Pond G, Hertz P, Amir E, Ocana A, Tannock IF. Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. Ann Oncol. 2012; 23: 2977-82. Impact Factor 6.578. Coauthor or Collaborator.

Eitan AMIR



99. Amir E, Bedard PL, Ocaña A, Seruga B. Benefits and Harms of Detecting Clinically Occult Breast Cancer. J Natl Cancer Inst. 2012 ; 104: 1542-1547. Impact Factor 15.161. Principal Author.

100. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012; 38: 708-714. Impact Factor 6.466. Principal Author.

101. Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee A, Savas S, Mackay HJ, Amir E, Liu G. Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clin Cancer Res. 2012; 18: 4526-4537. Impact Factor 8.193. Coauthor or Collaborator.

102. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E. The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012; 30: 3012-3019. Impact Factor 17.96. Senior Responsible Author.

103. Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol. 2012; 32: 2979-91. Impact Factor 5.036. Coauthor or Collaborator.

104. Ocana A, Amir E, Yeung C, Seruga B, Tannock IF. How valid are claims for synergy in published clinical studies? Ann Oncol. 2012; 23: 2161-6. Impact Factor 6.578. Coauthor or Collaborator.

105. Fralick M, Hilton JF, Bouganim N, Clemons M, Amir E. Dual blockade of Her2 – twice as good or twice as toxic? Clin Oncol (R Coll Radiol). 2012; 24: 593-603. Impact Factor 2.826. Senior Responsible Author.

106. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. A prospective study evaluating the impact of tissue confirmation of metastatic disease in breast cancer patients. J Clin Oncol. 2012; 30: 587-92. Impact Factor 17.96. Principal Author.

107. Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N and Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat. 2012; 133: 1077-88. Impact Factor 4.198. Principal Author.

108. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J Clin Oncol. 30: 1934-1940. Impact Factor 17.96. Coauthor or Collaborator.

109. Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay HJ. Genetic Polymorphisms as Predictive and Prognostic Biomarkers in Gynecological Cancers: A Systematic Review. Gyn Oncol. 2012; 124: 354–365. Impact Factor 3.687. Coauthor or Collaborator.

110. Dranitsaris G, Truter I, Lubbe MS, Amir E, Evans W. Advances in Cancer Therapeutics and Patient Access to New Drugs. Pharmacoeconomics. 2011; 29: 213-24. Impact Factor 3.338. Coauthor or Collaborator.

111. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, Wheatley-Price P, Hung RJ, Shepherd FA, Liu G. Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. J Thor Oncol. 2011; 6: 296-304. Impact Factor 5.8. Coauthor or Collaborator.

112. Florescu A, Bouganim N, Amir E, Clemons M. Immune therapy for breast cancer in 2010 – hype or hope? Curr Oncol. 2011 18: e9-18. Impact Factor 1.643. Coauthor or Collaborator.

113. Freedman OC, Amir E, Zimmermann C, Clemons M. Filling in the Gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Support Care Cancer. 2011; 19: 315-22. Impact Factor 2.495. Coauthor or Collaborator.

114. Dranitsaris G, Amir E, Dorward K. Biosimilars of Biological Drug Therapies: Regulatory, Clinical and Commercial Considerations. Drugs. 2011; 71: 1527-36. Impact Factor 4.133. Coauthor or Collaborator.

115. Amir E, Khayat D, Boyle P, Autier P, Tannock IF. Delivering affordable cancer care in high-income countries: Part 2: Research and cost-effectiveness in cancer care. Lancet Oncol. 2011; 12: 933-980. Impact Factor 24.725. Coauthor or Collaborator.

Eitan AMIR



116. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer. 2011; 19: 1687-96. Impact Factor 2.495. Coauthor or Collaborator.

117. Teuffel O, Amir E, Alibhai SMH, Beyene J, Sung L. Cost-Effectiveness of Outpatient Management for Febrile Neutropenia in Children with Cancer. Pediatrics. 2011; 127: e279-86. Impact Factor 5.297. Coauthor or Collaborator.

118. Teuffel O, Amir E, Alibhai S, Beyene J, Sung L. Cost-effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer. 2011; 104: 1377-83. Impact Factor 4.817. Coauthor or Collaborator.

119. Ouellet V, Mourskaia A, Tiedemann K, Fong J, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komorova S, Siegel PM. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favour breast cancer metastasis to bone. Am J Pathol. 2011; 178: 2377-88. Impact Factor 4.602. Coauthor or Collaborator.

120. Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Oncogenic targets, magnitude of benefit and market pricing of anti-neoplastic drugs. J Clin Oncol. 2011; 29: 2543-2549. Impact Factor 17.96. Principal Author.

121. Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB. An Economic Analysis of the INTEREST Trial, a Randomized Trial of Docetaxel versus Gefitinib as 2nd/3rd Line Therapy in Advanced Non-Small Cell Lung Cancer. Ann Oncol. 2011; 22: 1805-11. Impact Factor 6.578. Coauthor or Collaborator.

122. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2011; 103: 1299-1309. Impact Factor 15.161. Principal Author.

123. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, Done SJ, Gianfelice D, Kanji F, Dent S, Barth D, Bouganim N, Al-Najjar A, Clemons M. Acquisition of Metastatic Tissue From Patients with Bone Metastases from Breast Cancer. Breast Cancer Res Treat. 2011; 129: 761-5. Impact Factor 4.198. Coauthor or Collaborator.

124. Freedman OC, Amir E, Hanna W, Kahn H, O’Malley F, Dranitsaris G, Cole DEC, Verma S, Folkerd E, Dowsett M, Clemons M. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2010; 119: 155-61. Impact Factor 4.198. Coauthor or Collaborator.

125. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DEC, Vieth R, Ooi WS, Clemons M. A Phase II Trial Exploring The Effects Of High-Dose (10,000 IU/day) Vitamin D3 In Breast Cancer Patients With Bone Metastases. Cancer. 2010; 116: 284-91. Impact Factor 4.901. Co-Principal Author.

126. Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat. 2010; 122: 609-17. Impact Factor 4.198. Senior Responsible Author.

127. Amir E, Ocana A, Seruga B, Freedman O, Clemons M. Lapatinib and HER2 Status: Results of a Meta-analysis of Randomized Phase III Trials in Metastatic Breast Cancer. Cancer Treat Rev. 2010; 36: 410-415. Impact Factor 6.466. Principal Author.

128. Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. The incidence of Taxane-Induced pain and distress in patients receiving chemotherapy for early stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol. 2010; 17: 42-7. Impact Factor 1.643. Coauthor or Collaborator.

129. Amir E, Freedman O, Seruga B, Evans DG. Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. J Natl Cancer Inst. 2010; 102: 680–691. Impact Factor 15.161. Principal Author.

130. Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treat Rev. 2010; 36: 557-65. Impact Factor 6.466. Principal Author.

131. Amir E, Freedman OC, Allen L, Colgan T, Clemons M. Defining Ovarian Failure in Amenorrheic Young Breast Cancer Patients. Breast. 2010; 19: 545-8. Impact Factor 2.581. Principal Author.

Eitan AMIR



132. Freedman OC, Amir E, Clemons M. Adjuvant Bisphosphonate therapy for Breast Cancer Patients: Standard of Care or Future direction? Crit Rev Oncol Hematol. 2009; 72: 56-64. Impact Factor 4.046. Coauthor or Collaborator.

133. Amir E, Mandoky L, Blackhall F, Thatcher N, Klepetko W, Ankersmit HJ, Reza-Hoda MA, Ostoros G, Dank M, Dome B. Antivascular agents for non-small cell lung cancer: current status and future directions. Expert Opin Investig Drugs. 2009; 18: 1667-86. Impact Factor 5.432. Principal Author.

134. Ocana A, Amir E. Irreversible pan-ErbB Tyrosine Kinase Inhibitors and Breast Cancer: Current Status and Future Directions. Cancer Treat Rev. 2009; 35: 685-91. Impact Factor 6.466. Senior Responsible Author.

135. Trinkaus M, Ooi WS, Amir E, Popovic S, Kalina M, Kahn H, Singh G, Gainford MC, Clemons M. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer. Oncol Rep. 2009; 21: 1153-1160. Impact Factor 2.191. Coauthor or Collaborator.

136. Amir E, Trinkaus M, Simmons C, Cole DEC, Dranitsaris G, Clemons M. Vascular Endothelial Growth Factor (VEGF) Activity Following Second-line Bisphosphonate Treatment for Metastatic Breast Cancer. J Clin Pathol. 2009; 62: 474-476. Impact Factor 2.551. Principal Author.

137. Amir E, Whyne C, Freedman OC, Fralick M, Kumar R, Hardisty M, Clemons M. Radiological Changes Following Second-Line Zoledronic Acid Treatment in Breast Cancer Patients with Bone Metastases. Clin Exp Metastasis. 2009; 26: 479-84. Impact Factor 3.725. Principal Author.

138. Simmons C, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DEC. Calcium Metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer. Anticancer Res. 2009; 29: 2707-11. Impact Factor 1.872. Coauthor or Collaborator.

139. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. Am J Pathol. 2009; 175: 808-816. Impact Factor 4.602. Coauthor or Collaborator.

140. Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, Dent S, Tonkin K, Ahmad I, Rayson D, Clemons M. Predicting Benefit from Fulvestrant in Pretreated Metastatic Breast Cancer Patients. Breast Cancer Res Treat. 2009; 118: 377-83. Impact Factor 4.198. Coauthor or Collaborator.

141. Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ, Clemons M. Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis. 2009; 26: 935-43. Impact Factor 3.725. Coauthor or Collaborator.

142. Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, Howell A. Addition of breast cancer pathological correlates significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet. 2009; 46: 811-7. Impact Factor 5.636. Coauthor or Collaborator.

143. Al Husaini H, Amir E, Fitzgerald B, Wright F, Dent R, Fralick J, Clemons M. Prevalence Of Overt Metastases In Locally Advanced Breast Cancer. Clin Oncol (R Coll Radiol). 2008; 20: 340-344. Impact Factor 2.826. Coauthor or Collaborator.

144. Amir E, Ooi WS, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. Discordance Between Hormone and HER2/Neu Receptor Status in Primary Breast Cancer and Bone Metastases: Can Bone Marrow Biopsies Help Guide Future Treatment? Clin Oncol (R Coll Radiol). 2008; 20: 763-768. Impact Factor 2.826. Principal Author.

145. Amir E, Griffiths RW, Leahy MG. Brostallicin hydrochloride. Drugs Fut. 2008, 33: 478-488. Impact Factor 0.253. Principal Author.

146. Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Timar J, Tovari J, Kenessey I, Dome B. Targeting blood vessels for the treatment of non-small cell lung cancer. Curr Cancer Drug Targets. 2008, 8: 392-403. Impact Factor 3.582. Principal Author.

Eitan AMIR



147. Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004; 41: 474-480. Impact Factor 5.636. Coauthor or Collaborator.

148. Amir E, Evans DGR, Shenton A, Lalloo F, Moran A, Boggis CRM, Wilson M, Howell A. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003; 40: 807-14. Impact Factor 5.636. Principal Author.

Editorials

1. Thavendiranathan P, Amir E. Left ventricular dysfunction with trastuzumab therapy – is primary prevention the best option? J Clin Oncol. 2017 Mar;35(8):820-825. Impact Factor 20.982. Senior Responsible Author.

2. Srikanthan A, Amir E. Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practice. Eur J Cancer. 2015 May;51(8):905-6. Impact Factor 4.819. Senior Responsible Author.

3. Spreafico A, Amir E, Siu LL. Demystifying the Role of Tumor HPV Status in the Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Ann Oncol. 2014 Apr. 2014; 25: 760-2. Impact Factor 6.578. Coauthor or Collaborator.

4. Amir E, Goodwin PJ. Breast Cancer Chemoprevention Gets Personal. J Clin Oncol. 2011; 29: 2296-2298. Impact Factor 17.96. Principal Author.

Commentaries

1. Gómez García S, Clemons M, Amir E. Rethinking Endpoints for Bone-targeted therapy in Advanced Cancer. Eur J Cancer. 2016 Aug;63:105-109. Impact Factor 5.417. Senior Responsible Author.

2. Ocana A, Amir E, Tannock IF. Toward a value-based pricing to boost cancer research and innovation. Cancer Res. 2016 Jul;76(11):3127-9. Impact Factor 9.329. Coauthor or Collaborator.

3. Niraula S, Ocana A, Amir E. One step forward, two steps back: The story of everolimus in advanced breast cancer. Breast. 2015 Oct;24(5):529-531. Impact Factor 2.581. Senior Responsible Author.

4. Ocaña A, Seruga B, Amir E. Pathological Complete Response and Accelerated Approval of New Drugs in Breast Cancer. Lancet. 2015 Jan;385(9963):113. Impact Factor 39.207. Senior Responsible Author.

5. Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Poor Correlation Between Progression-Free and Overall Survival in Modern Clinical Trials: Are Composite Endpoints the Answer? Eur J Cancer. 2012; 48: 385-388. Impact Factor 4.819. Principal Author.

6. Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol. 2011 29: 254-256. Impact Factor 17.96. Coauthor or Collaborator.

7. Ocana A, Amir E, Seruga B. Clinical research: show us the data! J Clin Oncol. 2011; 29: 1099-1100. Impact Factor 17.96. Co-Principal Author.

8. Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Dose dense chemotherapy for triple negative breast cancer. Nat Rev Clin Oncol. 2010; 7: 79-80. Impact Factor 15.696. Principal Author.

9. Amir E, Ocana A, Seruga B, Josse R, Clemons M. Zoledronic acid for breast cancer therapy induced bone loss. Nat Rev Clin Oncol. 2010; 7: 187-188. Impact Factor 15.696. Principal Author.

10. Amir E, Clemons M. Should a biopsy be recommended for confirmation of metastatic disease in women with breast cancer? Lancet Oncol. 2009; 10: 933-935. Impact Factor 24.725. Principal Author.

11. Amir E, Seruga B, Freedman OC, Clemons M. Amenorrhoea, menopause, and endocrine therapy for breast cancer. BMJ. 2009; 339: b4261. Impact Factor 16.378. Principal Author.

Eitan AMIR



12. Amir E, Tannock IF. Androgen Deprivation and Bone Loss in Prostate Cancer. Nat Rev Urol. 2009; 6: 642-644. Impact Factor 4.522. Principal Author.

2. NON-PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Kuchuk I, Paterson A, Amir E, Clemons M, Bouganim N. Treatment recommendations for the use of bone-targeted agents in 2011—report from the 6th Annual Bone and the Oncologist New Updates meeting. Curr Oncol. 2012; 19: e364-370;. Impact Factor 1.643. Coauthor or Collaborator.

2. Bouganim N, Amir E, Clemons M. The 5th Annual Bone and the Oncologist New Updates (BONUS 5), National Arts Centre, Ottawa, April 8-9, 2010. Curr Oncol. 2010; 17: 113-8. Impact Factor 1.643. Coauthor or Collaborator.

Book Chapters

1. Amir E, Tannock IF. Chapter 22: Guide to Clinical Studies. In: Tannock IF, Hill RP, Bristow RG, Harrington L, editor(s). The Basic Science of Oncology. 5th ed. McGraw-Hill; 2013. p. 529-552.

2. Seruga B, Amir E, Tannock IF. Hormonal Anticancer Treatment in the Senior Cancer Patients. In: Schrijvers D, Aapro M, Zakotnik B, Audisio R, van Halteren H, Hurria A (Eds). European Society for Medical Oncology: Handbook of Cancer in the Senior Patient. p46-56, Informa Healthcare USA 2010. Coauthor or Collaborator.

3. Taylor SK, Freedman OC, Amir E, Clemons M. Bisphophonates in the Management of Bone Metastases. In: Eds: Sahgal A, Chow E, Merrick J (Eds.). Bone and Brain Metastases: Advances in Research and Treatment. Chapter 9, Nova Publishers 2010. Coauthor or Collaborator.

4. Amir E, Whorwell PJ. Lactose and Fructose Intolerance. In: Pawankar R, Holgate ST, Rosenwasser LJ (Eds.). Allergy Frontiers: Clinical Manifestations Vol. 3, p431-448, Springer 2009. Principal Author.

Letters to Editor

1. Ocana A, Vera-Badillo F, Templeton A, Tannock I, Amir E. Response. J Natl Cancer Inst. 2015 Aug;107(10):djv244. 2014. Impact Factor 12.58. Senior Responsible Author.

2. Ocana A, Diez-Gonzalez L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E. Tumor Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time? J Clin Oncol. 2015 Apr;33(11):1298-1299. 2014. Impact Factor 17.96. Senior Responsible Author.

3. Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. J Clin Oncol. 2014 Oct. 32(28):3197. Impact Factor 17.96. Coauthor or Collaborator.

4. Ocana A, Seruga B, Amir E. The multi-dimensional challenges in clinical drug development, regulatory approval and marketing. J Clin Oncol. 2013; 31: 1252-3. Impact Factor 17.96. Senior Responsible Author.

5. Seruga B, Ocana A, Niraula S, Amir E. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: Should we know more? J Clin Oncol. 2010; 28: e346-7. Impact Factor 17.96. Senior Responsible Author.

6. Ocana A, Amir E, Seruga B, Pandiella A. Do we have to change the way targeted drugs are developed? J Clin Oncol. 2010; 28: e420-1. Impact Factor 17.96. Coauthor or Collaborator.

7. Amir E, Freedman O. Underestimation Of Risk By Gail Model Extends Beyond Women With Atypical Hyperplasia. J Clin Oncol. 2009; 27: 1526. Impact Factor 17.96. Principal Author.

Eitan AMIR



8. Amir E, Seruga B, Freedman OC, Tannock IF. Lapatinib Plus Paclitaxel As First-Line Therapy for HER-2-positive Metastatic Breast Cancer Patients: Inappropriate Conclusions From A Company-Sponsored Study? J Clin Oncol. 2009; 27: 1919. Impact Factor 17.96. Principal Author.

9. Seruga B, Amir E, Tannock I. Treatment of Lung Cancer. N Engl J Med. 2009; 361: 2485. Impact Factor 54.42. Coauthor or Collaborator.

Monographs

1. Clemons M, Amir E, Haynes AE, Eisen A, Trudeau M. Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer. CED-CCO Special Advice Report #16. Cancer Care Ontario 2010. Coauthor or Collaborator.

F. Presentations and Special Lectures

1. INTERNATIONAL

Invited Lectures and Presentations

2017 Feb 7 Invited Speaker. Methodologic Considerations in the Interpretation of Trials in Advanced Breast Cancer. The Christie NHS Foundation Trust. Manchester, Manchester, United Kingdom.

2016 Oct 5 Invited Speaker. Cancer and Its Treatment: A physician’s insight. University of Salford. Manchester, Manchester, United Kingdom.

2016 Sep 27 Invited Speaker. Nature of Cancer. Faculty of Occupational Medicine. London, London, City of, United Kingdom. (Continuing Education).

2016 Mar 30 Invited Speaker. Cancer and Work: Oncologist’s Perspective. European Cooperation in Science and Technology: Cancer and Work Network (CANWON). Manchester, Manchester, United Kingdom. (Continuing Education).

2016 Mar 29 Invited Speaker. Systematic Review and Meta-analysis. The Christie NHS Foundation Trust. Manchester, Manchester, United Kingdom. (Continuing Education).

2015 Nov 14 Invited Speaker. Impact of genomics in the treatment of breast cancer. A.C. Camargo Cancer Center. Sao Paolo, São Paulo, Brazil. (Continuing Education).

2015 Oct 5 Invited Speaker. Cancer and Its Treatment: A physician’s insight. University of Salford. Manchester, Manchester, United Kingdom.

2015 Jun 20 Invited Speaker. Clinical Research: A critical appraisal. Grupo Español de Investigación en Cáncer de Mama. Madrid, Madrid, Spain.

2015 Jun 19 Invited Speaker. Breast Cancer Clinical Trials: A critical appraisal. Albacete University Hospital. Albacete, Albacete, Spain.

2015 May 26 Invited Speaker. Methodologic Issues in Breast Cancer Research: Focus on Meta-analysis. Davidoff Center. Petach Tikva, HaMerkaz, Israel. (Continuing Education).

2014 Dec 2 Invited Speaker. The role of androgen receptor in breast cancer. European School of Oncology. Milano, Milano, Italy.

2014 Nov 7 Invited Speaker. Toxicity of and Compliance with Endocrine Therapy. Fondazione Michelangelo. Milano, Milano, Italy.

Eitan AMIR



2013 Nov 7 Invited Speaker. Debate: Bone-specific therapy is NOT an integral part of the management of all patients with bone metastases. International Bone and Mineral Society. Miami, Florida, United States.

2013 Oct 19 Invited Speaker. Case Studies in Metastatic Breast Cancer. Oncology Leader’s Summit 2013. Geneve, Genève (fr), Switzerland.

2013 Apr 4 Invited Speaker. Adjuvant Endocrine Therapy in Early Breast Cancer: The State of the Art. Soroka Medical Center. Beer Sheva, HaDarom, Israel.

2013 Apr 2 Invited Speaker. Optimizing the Tailored Treatment of Breast Cancer. Davidoff Cancer Center, Rabin Medical Center. Petach Tikva, HaMerkaz, Israel. (Continuing Education).

2010 Dec Toxicity of adjuvant endocrine therapy in post-menopausal breast cancer patients. San Antonio Breast Cancer Symposium.

2010 Jun Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. American Society for Clinical Oncology Annual Meeting.

2009 Jun Discordance between hormone receptor profile of primary breast cancer and metastatic bone disease: should bone marrow biopsy be considered a standard of care? VIII Madrid Breast Cancer Conference.

2009 Mar A Phase II Trial Exploring The Effects Of High Dose (10,000 IU/day) Vitamin D In Breast Cancer Patients With Bone Metastases. VIII International Meeting on Cancer Induced Bone Disease.

2009 Mar An Exploratory Study of the Differential Expression of Candidate Genes in Bone Metastasis Biopsies and Bone Marrow Aspirates From the Same Patient. VIII International Meeting on Cancer Induced Bone Disease.

2009 Mar Skeletal related events (SREs) in patients with bone metastases from breast cancer treated with intravenous (i.v.) bisphosphonates (BPs) in the non-trial setting. VIII International Meeting on Cancer Induced Bone Disease.

Presented Abstracts

2009 Jun Biopsy confirmation of metastatic breast cancer: interim results of a prospective biopsy study (Poster Presentation). VIII Madrid Breast Cancer Conference.

2009 Jun A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor positive locally advanced breast cancer (Poster Presentation). VIII Madrid Breast Cancer Conference.

2009 May Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients (Poster Presentation). American Society for Clinical Oncology, May/June 2009.

2009 Mar Discordance Between Hormone Receptor Profile of Primary Breast Cancer and Metastatic Bone Disease: Should Bone Marrow Biopsy be Considered a Standard of Care? (Poster Presentation). VIII International Meeting on Cancer Induced Bone Disease.

2009 Mar Trials and Trepidations – Setting Up A Canadian Bone Metastasis Research Program (Poster Presentation). VIII International Meeting on Cancer Induced Bone Disease.

2. NATIONAL


2016 Jun 21 Invited Speaker. Should I believe the hype? Methodologic Considerations in the Interpretation of Trials in Advanced Breast Cancer. CancerCare Manitoba. Winnipeg, Manitoba, Canada. (Continuing Education).

Eitan AMIR



2015 Apr 24 Invited Speaker. Echocardiography and cardiotoxicity of cancer therapy. Canadian Society of Echocardiography. Toronto, Ontario, Canada.

2015 Apr 17 Invited Speaker. Are there limitations to bone-targeted agents for patients with bone metastases? The Ottawa Hospital Cancer Centre. Ottawa, Ontario, Canada.

2014 Apr 25 Invited Speaker. Adjuvant bisphosphonates DO NOT represent a gold-standard for post-menopausal women with higher risk breast cancer. The Ottawa Hospital Cancer Centre. Ottawa, Ontario, Canada.

2013 Nov 15 Invited Speaker. Impact of Biosimilars on Clinical Practice. Canadian Association of Pharmacy in Oncology. Vancouver, British Columbia, Canada.

2013 Jun 21 Invited Speaker. Follow-up for Early Breast Cancer. Canadian Breast Cancer Symposium. Toronto, Ontario, Canada.

2013 Jun 21 Chair. Neoadjuvant Therapy. Canadian Breast Cancer Symposium. Toronto, Ontario, Canada.

2013 Jun 20 Invited Speaker. Case Presentations on Metastatic Breast Cancer. Canadian Breast Cancer Symposium. Toronto, Ontario, Canada.

2013 Apr 12 Invited Speaker. Debate: Bone specific therapy in metastasic disease: should we curb our enthusiasm? The Ottawa Hospital Cancer Centre. Ottawa, Ontario, Canada.

2012 Apr 27 Invited Speaker. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: Is it time to “switch” strategy? Canadian Society of Surgical Oncology. Toronto, Ontario, Canada.

2012 Apr 24 Invited Speaker. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: Is it time to “switch” strategy? Le Centre des Maladies du Sein Deschenes-Fabia. Quebec City, Quebec, Canada.

2012 Apr 20 Invited Speaker. Debate: Benefit from adjuvant bisphosphonates is NOT associated with low estrogen states. The Ottawa Hospital Cancer Centre. Ottawa, Ontario, Canada.

2012 Apr 16 Invited Speaker. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: Is it time to “switch” strategy? Centre hospitalier de l’Université de Montréal. Montreal, Quebec, Canada.

2012 Jan 20 Invited Speaker. Genomics and Breast Cancer. Candian Cancer Society. Hamilton, Ontario, Canada.

2008 Oct Invited Speaker. Bone Metastases Biopsy Program – Where have we been and where are we going? McGill Musculoskeletal Axis Bi-annual Meeting.

2006 Mar Case Studies of Transcatheter Embolisation for Upper Gastrointestinal Haemorrhage: A valid alternative when medical management fails. Society for Acute Medicine Spring Meeting.

Presented Abstracts

2008 Jan Tarceva in Relapsed Non-small Cell Lung Cancer: Experience from Northwest England (Poster Presentation). British Thoracic Oncology Group Annual Meeting.

3. PROVINCIAL / REGIONAL


2016 Sep 22 Invited Speaker. Methodologic Considerations in the Interpretation of Trials in Advanced Breast Cancer. The Ottawa Hospital Cancer Centre. Ottawa, Ontario, Canada. (Continuing Education).

2016 Mar 10 Invited Speaker. Oncology Emergencies (and urgencies). Mackenzie Health Emergency Department. Richmond Hill, Ontario, Canada. (Continuing Education).

Eitan AMIR



2014 Apr 24 Invited Speaker. Screening Mammography: where are we now and where are we going? The Ottawa Hospital Cancer Program Grand Rounds. Ottawa, Ontario, Canada.

2013 Oct 24 Invited Speaker. Screening Mammography: hazardous? Queen’s University Department of Obstetrics & Gynaecology 36th Annual Memorial Program. Kingston, Ontario, Canada. (Continuing Education).

2012 Jan 18 Invited Speaker. Personalizing Systemic Therapy for Breast Cancer. London Pharmacogenomics Research Group. London, Ontario, Canada.

4. LOCAL


2017 Mar 22 Invited Speaker. Screening for Cancer _What have we learned from breast cancer screening and surveillance? Department of Family and Community Health. Toronto, Ontario, Canada.

2016 Sep 8 Invited Speaker. Should I believe the hype? Methodologic Considerations in the Interpretation of Trials in Advanced Breast Cancer. Princess Margaret Cancer Centre. Toronto, Ontario, Canada. (Continuing Education).

2016 Apr 20 Invited Speaker. Screening Mammography: where are we now and where are we going? Department of Family and Community Health. Toronto, Ontario, Canada.

2015 Sep 22 Invited Speaker. Methodologic Issues in Breast Cancer Systemic Therapy Trials. Princess Margaret Hospital Breast Group. Toronto, Ontario, Canada. (Continuing Education).

2015 Apr 14 Invited Speaker. The Androgen Receptor and Breast Cancer. Princess Margaret Hospital Breast Group. Toronto, Ontario, Canada. (Continuing Education).

2015 Mar 3 Invited Speaker. San Antonio Breast Cancer Symposium 2014: A Medical Oncologist’s Perspective. Princess Margaret Hospital Breast Group. Toronto, Ontario, Canada. (Continuing Education).

2013 Mar 14 Invited Speaker. Management of small HER2 overexpressing tumours. Mount Sinai Hospital Oncology Group. Toronto, Ontario, Canada.

2013 Feb 19 Invited Speaker. San Antonio Breast Cancer Symposium 2012: A Brief Overview. Princess Margaret Hospital Breast Group. Toronto, Ontario, Canada. (Continuing Education).

2013 Feb 5 Invited Speaker. Management of small HER2 overexpressing tumours. Princess Margaret Hospital Breast Group. Toronto, Ontario, Canada.

2013 Jan 15 Invited Speaker. The Evolution of a “Functional” Health Care Team. Psychosocial Oncology and Palliative Care Complex Care Rounds. Toronto, Ontario, Canada.

2012 Sep 4 Invited Speaker. Medical Management of Bone Metastases in Breast Cancer. Princess Margaret Hospital, Breast Group. Toronto, Ontario, Canada.

2012 May 1 Invited Speaker. Benefits and Harms of Detecting Clinically Occult Breast Cancer. Princess Margaret Hospital, Breast Group. Toronto, Ontario, Canada.

2010 Oct Invited Speaker. What’s New in Breast Cancer in 2010. 10th Princess Margaret Hospital Conference, The Sheraton Centre, 28-30 Oct. Toronto, Ontario.

2009 Nov Invited Speaker. Pathobiology of Disease - Systemic Cancer Therapy. University of Toronto Medical School.

Eitan AMIR



G. Teaching and Design

As a teacher, I aim to help trainees by challenging them with problems and equipping them with critical thinking skills that can be applied to their clinical practice and research endeavours. From my prior experiences as a trainee, I consider effective teachers as being good professional role models for their students. I seek opportunity to supervise medical students, residents and clinical fellows. I am respective of their time prioritize their learning needs during clinical interactions.

H. Research Supervision

1. PRIMARY OR CO-SUPERVISION

Graduate Education

2016 Jul - 2018 Jun Primary Supervisor. MSc. Mark Doherty, Health Policy, Management and Evaluation. Supervisee Institution: University of Toronto.

2015 Jul - 2016 Nov Primary Supervisor. MSc. Josee-Lyne Ethier. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital.

Postgraduate MD

2016 Sep - 2018 Aug Primary Supervisor. Clinical Fellow. Hadar Goldvaser. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Influence of non-measureable disease on the interpretayion of progression-free survival in metastatic breast cancer.

2016 Sep - 2018 Aug Primary Supervisor. Clinical Fellow. Domen Ribnikar. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Reporting of results of oncology phase 3 clinical trials in the lay media.

2016 Jul - 2017 Jun Co-Supervisor. Clinical Fellow. Tristan Barnes. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Efficacy, safety, tolerability and price of newly approved anti-cancer drugs.

2015 Jul - 2017 Jun Primary Supervisor. Clinical Fellow. Josee-Lyne Ethier. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Tapered corticosteroids for taxane-induced arthralgia and myalgia.

2014 Feb - 2016 Jan Primary Supervisor. Clinical Fellow. Amirrtha Srikanthan. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Fertility preservation in young women requiring chemotherapy for breast cancer.

2013 Jul - 2015 Jun Primary Supervisor. Clinical Fellow. Hashem Al-Hashem. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Geographical Variations in Outcomes of Phase III RCTs in Cancer.

2012 Jul - 2014 Jun Primary Supervisor. Clinical Fellow. Mustafa Al-Mubarak. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Fulvestrant in Metastatic Breast Cancer: A Meta-analysis.

2012 Jul - 2013 Jun Primary Supervisor. Clinical Fellow. Francisco Vera-Badillo. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Androgen Receptor and Outcome in Early Breast Cancer. Collaborator(s): Ian Tannock.

Faculty Development

2013 Nov - 2014 Dec Primary Supervisor. Ariadna Tibau. Supervisee Position: Junior Staff, Supervisee Institution: Hospital de la Santa Creu i Sant Pau. Financial conflicts of interest in oncology clinical practice guidelines.

Eitan AMIR



2. OTHER SUPERVISION

Graduate Education

Thesis Committee Member

2016 Jun - 2017 Jun MSc. Katarzyna Jerzak, Health Policy, Management and Evaluation. Supervisee Position: Clinical Fellow, Supervisee Institution: University of Toronto. Obesity related factors and breast cancer.

2016 Jan - 2018 Jun PhD. Ana Lohmann, Health Policy, Management and Evaluation. Supervisee Position: Clinical Fellow, Supervisee Institution: University of Toronto. Obesity related factors and breast cancer.

2016 Jan - 2017 Jul MSc. Mustafa Abdul Selam, Medical Science. Supervisee Position: Clinical Fellow, Supervisee Institution: University of Toronto. Cardiac volumes, function and strain in a cohort of women with breast cancer treated with anthracyclines and trastuzumab.

2015 Jan - 2017 Jul MSc. Javaid Iqbal, Medical Science. Supervisee Position: Research Fellow, Supervisee Institution: University of Toronto. Effect of pregnancy on breast cancer outcomes.

2013 Jul - 2018 Jun PhD. Husam Abdel Qadir, Health Policy, Management and Evaluation. Supervisee Position: Clinical Fellow, Supervisee Institution: University of Toronto. Cardiovascular outcomes of anti-cancer drugs.

Postgraduate MD

Secondary Supervisor

2011 Jul - 2012 Jun Clinical Fellow. Francisco Vera-Badillo. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. Bias in reporting of clinical trials. Collaborator(s): Ian Tannock.

Thesis Committee Member

2013 Jan - 2014 Apr Clinical Fellow. Dr. Adewunmi Adeoye. Supervisee Position: Clinical Fellow, Supervisee Institution: Toronto General Hospital. Exploration of breast cancer prognostic factors using archival tissue microarrays.

I. Creative Professional Activities

1. PROFESSIONAL INNOVATION AND CREATIVE EXCELLENCE

2015 Apr - present Multi-disciplinary neoadjuvant breast cancer program. Designed a multi-disciplinary neoadjuvant breast cancer program to allow streamlined care of patients requiring neoadjuvant therapy. Secured funding for the program and chair the executive committee overseeing the program. More streamlined care of patients requiring neoadjuvant therapy.

2. CONTRIBUTIONS TO THE DEVELOPMENT OF PROFESSIONAL PRACTICES

2012 Aug - present Standards for the Safe Use of Oral Anti-Cancer Drugs. Recomended standards to be followed by institutions and staff involved in the prescribing, dispensing, supply, administration and monitoring of the use of oral anticancer medicines in the Toronto Central South region. Roll out of oral chemotherapy prescription guidelines and creation of pre-printed orders in

Eitan AMIR



hospitals comprising the Cancer Care Ontario Toronto Central South Region

2012 Jan - present Clinical Practice Guidelines: Breast Site Group. Multi-disciplinary guidelines of practice at the Princess Margaret Cancer Program. Standardization of surgical, radiation and systemic therapy and sharing of guidelines with the Kuwait Cancer Centre

cv eitan.amir 201751175337 - comprehensive …eitan amir page 4 of 27 generated by web cv - 2017 may...

Documents